Haydar Celik1, Paul Wakim2, William F Pritchard3, Meryll Castro3, Shelby Leonard3, John W Karanian3, Mark W Dewhirst4, Riccardo Lencioni5, Bradford J Wood3. 1. Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 3N320, Bethesda, MD 20892. Electronic address: haydar.celik@nih.gov. 2. Biostatistics and Clinical Epidemiology Service, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 3N320, Bethesda, MD 20892. 3. Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, 9000 Rockville Pike, Building 10, Room 3N320, Bethesda, MD 20892. 4. Duke Cancer Institute, Duke University, Durham, North Carolina. 5. Division of Diagnostic Imaging and Intervention, Pisa University School of Medicine, Pisa, Italy.
Abstract
PURPOSE: To determine whether burn time per tumor volume (BPV) (min/mL), where burn time is the total time during which radiofrequency (RF) energy is being applied, is correlated with hepatocellular carcinoma (HCC) treatment outcomes using RF ablation and lyso-thermosensitive liposomal doxorubicin (LTLD). MATERIALS AND METHODS: The HEAT study was a double-blind, randomized controlled phase III trial of RF ablation only versus RF ablation + LTLD in patients with HCCs 3-7 cm in diameter. Effect of BPV on progression-free survival and overall survival (OS) was analyzed. RESULTS:BPV demonstrated statistically significant differences between study groups for OS (P = .038, hazard ratio [HR] = 0.85), but not for progression-free survival (P = .389, HR = 1.059). In a separate analysis, treatment groups were independently analyzed to determine the effect of BPV within each individual group. OS improved as BPV increased for patients receiving RF ablation + LTLD (P = .017, HR = 0.836, confidence interval [0.722, 0.968]). This same association was not observed in patients receiving RF ablation only (P = .57, HR = 0.99). CONCLUSIONS:BPV may be a useful metric for RF ablation + LTLD combination therapy for solitary HCC. The analysis suggested that the burn time for the tumor needs to be adjusted depending on the tumor volume. Because this is a post hoc study, the results are only suggestive and need to be confirmed with prospective studies. Published by Elsevier Inc.
RCT Entities:
PURPOSE: To determine whether burn time per tumor volume (BPV) (min/mL), where burn time is the total time during which radiofrequency (RF) energy is being applied, is correlated with hepatocellular carcinoma (HCC) treatment outcomes using RF ablation and lyso-thermosensitive liposomal doxorubicin (LTLD). MATERIALS AND METHODS: The HEAT study was a double-blind, randomized controlled phase III trial of RF ablation only versus RF ablation + LTLD in patients with HCCs 3-7 cm in diameter. Effect of BPV on progression-free survival and overall survival (OS) was analyzed. RESULTS:BPV demonstrated statistically significant differences between study groups for OS (P = .038, hazard ratio [HR] = 0.85), but not for progression-free survival (P = .389, HR = 1.059). In a separate analysis, treatment groups were independently analyzed to determine the effect of BPV within each individual group. OS improved as BPV increased for patients receiving RF ablation + LTLD (P = .017, HR = 0.836, confidence interval [0.722, 0.968]). This same association was not observed in patients receiving RF ablation only (P = .57, HR = 0.99). CONCLUSIONS:BPV may be a useful metric for RF ablation + LTLD combination therapy for solitary HCC. The analysis suggested that the burn time for the tumor needs to be adjusted depending on the tumor volume. Because this is a post hoc study, the results are only suggestive and need to be confirmed with prospective studies. Published by Elsevier Inc.
Authors: A D Strickland; P J Clegg; N J Cronin; B Swift; M Festing; K P West; G S M Robertson; D M Lloyd Journal: Br J Surg Date: 2002-08 Impact factor: 6.939
Authors: L Solbiati; T Livraghi; S N Goldberg; T Ierace; F Meloni; M Dellanoce; L Cova; E F Halpern; G S Gazelle Journal: Radiology Date: 2001-10 Impact factor: 11.105
Authors: Bradford J Wood; Ronnie T Poon; Julia K Locklin; Matthew R Dreher; K K Ng; Michelle Eugeni; Geoffrey Seidel; Sergio Dromi; Ziv Neeman; Michael Kolf; Christopher D V Black; Raj Prabhakar; Steven K Libutti Journal: J Vasc Interv Radiol Date: 2011-12-16 Impact factor: 3.464
Authors: Won Young Tak; Shi-Ming Lin; Yijun Wang; Jiasheng Zheng; Aldo Vecchione; Soo Young Park; Min Hua Chen; Stephen Wong; Ruocai Xu; Cheng-Yuan Peng; Yi-You Chiou; Guan-Tarn Huang; Jianqiang Cai; Basri Johan Jeet Abdullah; June Sung Lee; Jae Young Lee; Jong-Young Choi; Julieta Gopez-Cervantes; Morris Sherman; Richard S Finn; Masao Omata; Michael O'Neal; Lukas Makris; Nicholas Borys; Ronnie Poon; Riccardo Lencioni Journal: Clin Cancer Res Date: 2017-10-10 Impact factor: 12.531
Authors: Ashley A Manzoor; Lars H Lindner; Chelsea D Landon; Ji-Young Park; Andrew J Simnick; Matthew R Dreher; Shiva Das; Gabi Hanna; Won Park; Ashutosh Chilkoti; Gerben A Koning; Timo L M ten Hagen; David Needham; Mark W Dewhirst Journal: Cancer Res Date: 2012-09-04 Impact factor: 12.701
Authors: Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni Journal: Nat Rev Gastroenterol Hepatol Date: 2021-01-28 Impact factor: 46.802